Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness of Vagus Nerve Stimulation VNS Therapy as an additional treatment for people with treatment-resistant depression. The study compares active VNS treatment with a no stimulation control over a 12-month period to see if VNS can reduce depressive symptoms measured by several depression scales. This is a prospective, multi-center, randomized, controlled, and blinded trial involving subjects who have VNS devices implanted. Participants receive the VNS implant, and after at least two weeks, they are randomized to either have the device activated or not activated for the first 12 months. Those in the control group can receive stimulation after 12 months. After the initial 12-month randomized phase, all participants transition into an open-label, long-term study lasting about 5 years. New subjects may also enroll directly into this extension phase. During the trial, participants are assessed regularly using multiple depression rating scales and questionnaires to monitor changes in symptoms, response times, remission, and adverse events. Safety and quality of life measures are also tracked. The study includes thorough monitoring of depressive symptoms and overall functioning for up to 12 months post-randomization, followed by long-term observation for several years.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of IMG-007 compared to placebo in adults with moderate-to-severe active atopic dermatitis. This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to understand how well IMG-007 works and its safety profile over a period of up to 48 weeks. Participants will receive subcutaneous injections of IMG-007 or placebo according to the study protocol. The study includes multiple dose regimens of IMG-007 and placebo groups, with some placebo participants crossing over to receive IMG-007 later. Treatments follow a parallel group design where different groups receive different doses or placebo. During the study, participants will undergo assessments including Eczema Area and Severity Index EASI scoring and Investigator Global Assessment for Atopic Dermatitis vIGA-AD at baseline and Week 24. Researchers will monitor treatment-emergent adverse events throughout the study. Participants will be followed for up to 48 weeks to evaluate changes in skin condition and safety outcomes during and after treatment.
Actively Recruiting
The trial investigates the safety and effectiveness of ruxolitinib cream in treating children with nonsegmental vitiligo, a condition causing loss of skin pigment. It is a Phase 3, randomized, double-blind study aimed at evaluating how well this topical treatment works in pediatric participants aged 2 to 11 years with limited body surface affected by vitiligo. Participants are randomly assigned to receive either ruxolitinib 1.5% cream or a matching vehicle cream, both applied twice daily as a thin film to the affected skin areas. The study measures improvements in facial and total body vitiligo using specific scoring indexes over 24 and 52 weeks. Participants must stop other vitiligo treatments during the trial and are monitored for safety throughout. Throughout the study, participants undergo assessments including evaluation of skin pigment improvement using Facial Vitiligo Area Scoring Index F-VASI and Total Body Vitiligo Area Scoring Index T-VASI. Safety is tracked by recording any adverse events up to 30 days after treatment. Pharmacokinetic tests measure drug concentration at multiple time points. The total study duration extends up to nearly four years, with ongoing follow-up to evaluate treatment effects and safety.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the effects of a novel bioactive leg sleeve compared to a placebo sleeve on pain and patient-reported outcomes after arthroscopic meniscectomy or meniscus repair. This randomized, double-blind study involves approximately 100 patients to assess whether the bioactive sleeve can reduce pain and improve recovery measures more effectively than a non-bioactive sleeve. The study focuses on pain scores, patient satisfaction, physical therapy time, and motor function. Participants will be randomly assigned to wear either the Reparel Leg Sleeve, which contains nano-sized semi-conductive materials designed to emit photonic energy for pain relief and healing, or a similar-looking placebo sleeve without this technology. Both sleeves come in multiple sizes and are intended for postoperative use. The study tracks patient outcomes before surgery and at multiple time points up to two years after the procedure. During the study, participants will complete various patient-reported outcome measures such as pain scales and function questionnaires before surgery and at 1 week, 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years postoperatively. Researchers will also monitor range of motion and other physical recovery indicators. The study aims to understand the impact of the bioactive sleeve on long-term pain and healing after meniscal surgery.
Actively Recruiting
Researchers are evaluating the effectiveness and long-term safety of PP405, a medicated topical gel, for treating Androgenetic Alopecia in adult males aged 18 to 55. This phase 23 randomized, double-blind study involves men who have experienced hair loss for at least six months and have specific severity scores on the Norwood-Hamilton scale. Participants are randomly assigned to receive either PP405 topical gel or a non-medicated vehicle gel applied to the scalp once daily for 24 weeks. After this initial period, those on PP405 continue the treatment while participants initially on the vehicle are re-randomized to either PP405 or vehicle for an additional 28 weeks, creating a total treatment duration of 52 weeks to assess both efficacy and safety over time. Throughout the study, participants will be regularly assessed for changes in hair count and scalp coverage using both clinical and participant evaluations at weeks 12 and 24. Safety monitoring continues during the extension phase up to week 52. The primary outcome focuses on the change in non-vellus target area hair count at week 24, with secondary measures including participant assessments of scalp coverage and hair count improvements at weeks 12 and 24.
Actively Recruiting
Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BrainsWay Deep Transcranial Magnetic Stimulation Deep TMS for reducing heavy drinking in adults diagnosed with moderate to severe Alcohol Use Disorder AUD. This prospective, double-blind, randomized controlled trial involves outpatients aged 18 to 86 years, recruited from multiple academic and private research centers. The study compares active Deep TMS treatment to a sham treatment over a period extending up to 6 months. Participants are randomly assigned to either the Deep TMS group or the sham treatment group in a 11 ratio. The acute treatment phase includes 15 visits over 3 to 5 weeks, where each visit consists of two treatment sessions spaced 30 minutes apart, each lasting about 20 minutes. Following this, the maintenance and follow-up phase involves weekly treatment sessions continuing until the 6-month follow-up visit. Alcohol-related cues are presented before each stimulation session to assess responses. During the study, participants undergo assessments of alcohol use and craving using various scales, including the primary efficacy measure focusing on the percentage of heavy drinking days during months 2 to 4. Safety is monitored through tracking adverse events, vital signs, and neurological and physical examinations. The trial includes structured monitoring and follow-up visits throughout the treatment and maintenance phases, with participation lasting up to 6 months.
Actively Recruiting
Researchers are evaluating the safety, how the body absorbs and processes, and the treatment effects of CABTREO lotion when applied to the skin in children aged 9 to 11 years, 11 months who have moderate to severe acne vulgaris. The study is open-label and phase 4, focusing on pediatric participants with specific acne severity and lesion counts on the face and at least one trunk area. The purpose is to understand how well CABTREO works and how safe it is in this age group. Participants will apply CABTREO, a combination gel containing clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15%, to affected areas once each morning for 12 weeks. On study visit days, participants will apply the gel at the study center after assessments. The study includes a main group and a smaller pharmacokinetics PK sub-study group to examine drug levels in the blood. The treatment is a topical gel gently rubbed into the skin. Participants will first complete a screening period of up to 5 weeks to confirm eligibility. During the 12-week treatment, they will attend visits at baseline and Days 14, 15 PK sub-study only, 28, 29 PK sub-study only, 56, and 84. Researchers will monitor safety by tracking any adverse events and measure changes in inflammatory and non-inflammatory acne lesions, as well as global acne severity scores. Participants must follow study instructions and attend visits with their parent or guardian if under age of consent.
Actively Recruiting
This research aims to assess the safety and effectiveness of deuruxolitinib in adolescents aged 12 to less than 18 years who have severe alopecia areata, characterized by 50% or greater scalp hair loss. The study includes a double-blind, randomized, placebo-controlled treatment phase followed by an open-label extension. The goal is to better understand how well deuruxolitinib works and how safe it is for this age group with significant hair loss. Participants will be randomly assigned to receive either deuruxolitinib tablets or matching placebo tablets taken orally twice daily for 24 weeks during the initial treatment period. Following this, all participants will have the opportunity to receive deuruxolitinib for an additional 52 weeks in an open-label extension phase. This design allows comparison of the drug to placebo and longer-term evaluation of the drugs effects. Throughout the study, participants will have regular assessments of their hair loss using the Severity of Alopecia Tool SALT at multiple time points up to week 24 and beyond. Safety will be closely monitored by tracking side effects, vital signs, heart tests, lab results, and physical exams. Additional measurements include patient and clinician impressions of improvement, quality of life, and mental health assessments. The total study duration can extend up to 76 weeks of treatment plus safety follow-up to fully evaluate outcomes and tolerability.